Levilimab - CISMeF

Preferred Label : Levilimab;

NCIt definition : An immunoglobulin G1 (IgG1) monoclonal antibody directed against the human interleukin-6 receptor (IL-6R; IL6R; CD126), with potential immunomodulating activity. Upon administration, levilimab targets and binds to the soluble form of IL-6R (sIL-6R; IL-6sR), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.;

UNII : P7UV3L2H80;

CAS number : 2035008-70-7;

Molecule name : BCD 089; BCD-089;

NCI Metathesaurus CUI : CL1407730;

Détails

Origin ID

C173804;

UMLS CUI

C5420393;

Currated CISMeF NLP mapping
- levilimab [MeSH Supplementary Concept]
- levilimab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- levilimab [MeSH Supplementary Concept]
- levilimab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients